NRXP Company Profile and Key Details

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) closed at $1.91 USD, gaining $0.23 (13.69%) from the previous close of $1.68. The stock is currently mid-range between its 52-week high and low $1.58 and $3.84. With a market capitalization of about $33.02 million, NRx Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.96). Key stats such as the average daily volume over the past year has been around 940.30 thousand shares, volume is running light vs its 52-week average. Headquartered in Wilmington, DE, NRx Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan C. Javitt, the company employs approximately 2 people and listed since December 04, 2017. NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

NRXP has shown weak momentum, losing -1.8% over the past week and -31.45% over the past quarter, though year-to-date performance is down -19.56%. Short-term trend indicators are bullishly aligned (SMA20 -9.91%, SMA50 -15.62%, SMA200 -28.81%). The stock’s 14-day RSI is 40.99 (neutral), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -50.26% below its high and over 20.89% above its low. Average 10-day trading volume of 665.81 thousand shares is below the 3-month average of 914.89 thousand, indicating normal recent market interest.

NRx Pharmaceuticals, Inc. has 23.77 million shares outstanding. The public float is 13.61 million shares, elevated short interest at 3.03% of float. This equals 545.48 thousand shares. The short ratio is 2.06 days. Institutional investors hold 28.8% of the float. Insiders own 11.55%. Javitt Daniel C. holds 9.63 million shares, Hurvitz Chaim has 570.00 thousand shares and Polar Asset Management Partners Inc. has 488.04 thousand shares.

NRx Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.49. This means the shares are trading below this model’s fair value.

The latest quarter delivered EPS of -$0.18. The next quarter is forecast at $0.01. Next year's EPS is expected at $49.45. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 30 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $48.00 to $18.00. The high target offers 2413.09% upside. The low target suggests 842.41% downside. The mean target is $32.67. This offers 1610.47% upside. NRx Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 63.64%. The prior quarter beat by 13.33%. Over the last six quarters, Apple has recorded several small beats. These include -99.91% in August 12, 2024.

NRx Pharmaceuticals, Inc. trades at a P/E ratio of -1.11, slightly below the S&P 500 average, with a price-to-sales ratio of 136.07 and a price-to-book ratio of -1.64 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.78, also above market averages.

Our AI price prediction model suggests that NRx Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.04%, with price expected at $1.68 by February 20, 2026, within a range of $1.51 to $1.85 3-Month Outlook: Projected rise of 117.28%, reaching $4.15 by May 06, 2026, with a range of $3.97 to $4.49. 1-Year Outlook: Projected gain of 139.27%, with price at $4.57 by February 05, 2027, within a range of $0.00 to $5.22.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) shares are down -19.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NRx Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -1.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.51, suggesting 1497.38% upside. Our AI forecast model points to short-term weakness (-12.04% over two weeks), a medium-term rise (117.28% over three months), and a longer-term gain (139.27% over one year), with expected trading ranges indicating moderate volatility.